Evidence map›Paper›PMID 29879046›Full record

SynthesisMedicine2018

Clinical aspects of adherence to pharmacotherapy in Parkinson disease: A PRISMA-compliant systematic review.

Igor Straka, Michal Minár, Andrea Gažová, Peter Valkovič, Ján Kyselovič

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Supporting Medication Adherence in Parkinson's Through Education: A Scoping Review of Interventions.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Living with Parkinson's disease: disease and medication experiences of patients and caregivers.International journal of qualitative studies on health and well-being · 2022
    Article
  17. Article
  18. The impact of poor medication knowledge on health-related quality of life in people with Parkinson's disease: a mediation analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Igor StrakaSecond Department of Neurology, Faculty of Medicine Comenius University and University Hospital Bratislava Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine Comenius University Institute of Normal and Pathological Sciences, Slovak Academy of Sciences Department of Internal Medicine, Faculty of Medicine in Bratislava, Comenius University, Slovakia.
Michal Minár
Andrea Gažová
Peter Valkovič
Ján Kyselovič

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson disease (PD) is the second most common neurodegenerative disease with various motor and nonmotor symptoms. Progressive course of PD requires frequent medication adjustments. Various combinations of drugs and dose regimens could be used to control symptoms. Thus, not surprisingly, adherence to pharmacotherapy is frequently suboptimal in these patients having negative effect on motor control and patient's quality of life.

methodsIn this article, we offer up-to-date review of adherence in PD compared with other chronic conditions. In addition, we summarize factors influencing level of adherence, ways of measuring, and methods of adherence optimization. For the review of adherence in PD, a literature search was undertaken using PubMed database and relevant search terms. Articles were screened for suitability and data relevance.

resultsPubMed and Scopus databases were systematically searched in 2016 and data extraction was a multistep process based on the PRISMA Guidelines.

conclusionAccording to the recent data, sufficient control of motor symptoms and adequate quality of life are primary goals in the treatment of PD. Adherence to pharmacotherapy play a key role in this process, thus the medication should be tailored for each patient. In order to improve level of suboptimal adherence, these patients should have got recommended various dosing devices or alarms. Good communication with the patients and their relatives or caregivers is also essential.

Indexed as

Medication AdherenceAdultAgedChronic DiseaseCommunicationFemaleHumansMaleMiddle AgedParkinson DiseaseQuality of LifeTreatment Outcome

Identifiers

PMID29879046
PMCPMC5999496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.